These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37542187)

  • 1. Changes in expression of mesothelial BBS genes in 2D and 3D after lithium chloride and ammonium sulphate induction of primary cilium disturbance: a pilot study.
    Rouka E; Jagirdar RM; Sarrigeorgiou I; Pitaraki E; Sinis SI; Varsamas C; Papazoglou ED; Kotsiou OS; Lymberi P; Giannou A; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Pharmacol Rep; 2023 Oct; 75(5):1230-1239. PubMed ID: 37542187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pharmacological primary cilium disturbance in the context of in vitro 2D and 3D malignant pleura mesothelioma.
    Jagirdar RM; Pitaraki E; Kotsiou OS; Rouka E; Sinis SI; Varsamas C; Marnas P; Stergiopoulou E; Giannou A; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Biochem Biophys Res Commun; 2023 Apr; 654():128-135. PubMed ID: 36907140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
    Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benign Pleural Mesothelial Cells Have Higher Osmotic Water Permeability than Malignant Pleural Mesothelioma Cells and Differentially Respond to Hyperosmolality.
    Katkova LE; Baturina GS; Bondar AA; Jagirdar RM; Hatzoglou C; Gourgoulianis KI; Solenov EI; Zarogiannis SG
    Cell Physiol Biochem; 2019; 52(4):869-878. PubMed ID: 30958661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent.
    Jagirdar RM; Apostolidou E; Molyvdas PA; Gourgoulianis KI; Hatzoglou C; Zarogiannis SG
    Am J Physiol Lung Cell Mol Physiol; 2016 Mar; 310(6):L489-95. PubMed ID: 26773069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.
    Cioce M; Canino C; Pass H; Blandino G; Strano S; Fazio VM
    J Exp Clin Cancer Res; 2021 Nov; 40(1):344. PubMed ID: 34727953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
    Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
    Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
    Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.
    Bruno R; Alì G; Giannini R; Proietti A; Lucchi M; Chella A; Melfi F; Mussi A; Fontanini G
    Oncotarget; 2017 Jan; 8(2):2758-2770. PubMed ID: 27835874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
    J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma.
    Elshazley M; Sato M; Hase T; Yamashita R; Yoshida K; Toyokuni S; Ishiguro F; Osada H; Sekido Y; Yokoi K; Usami N; Shames DS; Kondo M; Gazdar AF; Minna JD; Hasegawa Y
    Int J Cancer; 2012 Dec; 131(12):2820-31. PubMed ID: 22510946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
    Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
    Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GAS5 long non-coding RNA in malignant pleural mesothelioma.
    Renganathan A; Kresoja-Rakic J; Echeverry N; Ziltener G; Vrugt B; Opitz I; Stahel RA; Felley-Bosco E
    Mol Cancer; 2014 May; 13():119. PubMed ID: 24885398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Primary Cilium Expression and Hedgehog Pathway Activation in Mesothelioma Throws Back Its Complex Biology.
    Barbarino M; Bottaro M; Spagnoletti L; de Santi MM; Guazzo R; Defraia C; Custoza C; Serio G; Iannelli F; Pesetti M; Aiello R; Rosati D; Zanfrini E; Luzzi L; Bellan C; Giordano A
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing clofazimine for malignant pleural mesothelioma treatment - In-vitro assessment of efficacy and mechanism of action.
    Parvathaneni V; Chilamakuri R; Kulkarni NS; Wang X; Agarwal S; Gupta V
    Life Sci; 2022 Oct; 306():120843. PubMed ID: 35908620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
    Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
    Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
    Borchert S; Suckrau PM; Walter RFH; Wessolly M; Mairinger E; Steinborn J; Hegedus B; Hager T; Herold T; Eberhardt WEE; Wohlschlaeger J; Aigner C; Bankfalvi A; Schmid KW; Mairinger FD
    Sci Rep; 2020 Oct; 10(1):18677. PubMed ID: 33122816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.